Cathay International Holdings Ld Result of AGM (6856B)

TIDMCTI

RNS Number : 6856B

Cathay International Holdings Ld

20 June 2016

Cathay International Holdings Limited

("Cathay" or the "Company")

Results of Annual General Meeting ("AGM")

Hong Kong, 20 June 2016 - Cathay International Holdings Ltd. (LSE: CTI.L), a leading operator and investor in the growing healthcare sector in the People's Republic of China, today announces that at the AGM held earlier today, all resolutions as set out in the Notice of AGM dated 22 April 2016 were duly passed. The final poll voting results for each resolution are shown in the table below:

 
 Ordinary resolutions                           For   Against         Total   Withheld 
                                                                      votes 
-------------------------------------  ------------  --------  ------------  --------- 
 1. Report and Accounts                 445,770,251   145,131   445,915,382     16,414 
-------------------------------------  ------------  --------  ------------  --------- 
 2. Re-election of 
  Mr. Lee Jin-Yi                        445,907,374    21,186   445,928,560      3,236 
-------------------------------------  ------------  --------  ------------  --------- 
 3. Re-election of 
  Mr. Siu Ka Chi Eric                   445,782,274   148,186   445,930,460      1,336 
-------------------------------------  ------------  --------  ------------  --------- 
 4. Re-election of 
  Mr. Patrick Sung                      445,782,274   148,186   445,930,460      1,336 
-------------------------------------  ------------  --------  ------------  --------- 
 5. Re-election of 
  Dr. Chan Ching Har 
  Eliza 
 
       *    all shareholders            445,902,620    27,480   445,930,100      1,336 
 
       *    independent shareholders     55,760,666    27,480    55,788,146      1,336 
-------------------------------------  ------------  --------  ------------  --------- 
 6. Reappointment 
  of Auditor                            445,777,450   151,110   445,928,560      3,236 
-------------------------------------  ------------  --------  ------------  --------- 
 7. Authority to 
  allot new shares                      445,787,573   139,456   445,927,029      4,767 
-------------------------------------  ------------  --------  ------------  --------- 
 
 
 Special resolutions               For      Against         Total   Withheld 
                                                            votes 
------------------------  ------------  -----------  ------------  --------- 
 8. Disapplication 
  of pre-emption rights    401,050,757   44,861,437   445,912,194     19,602 
------------------------  ------------  -----------  ------------  --------- 
 9. Authority to 
  purchase own shares      445,923,946        6,514   445,930,460      1,336 
------------------------  ------------  -----------  ------------  --------- 
 

Notes:

1. Any proxy votes which are at the discretion of the Chairman have been included in the 'For' total.

2. A vote 'Withheld' is not a vote in law and is not counted in the calculation of the proportion of the votes for and against a resolution.

A copy of the resolutions passed at the meeting is being uploaded today to the National Storage Mechanism and will shortly be available for viewing at www.morningstar.com.

The proxy figures for the resolutions will also be displayed on the Company website at www.cathay-intl.com.hk

- ENDS -

For further enquiries, please contact:

 
 Cathay International Holdings 
  Limited                               Tel: [phone] 
  Eric Siu (Finance Director) 
  Patrick Sung (Director and 
  Controller) 
 Consilium Strategic Communications 
  Mary-Jane Elliott / Matthew           Tel: +44 (0) 203 
  Neal / Lindsey Neville                709 5702 
 

About Cathay

Cathay International Holdings Limited (LSE: CTI.L) is a main market listed investment holding company and a leading operator and investor in the growing healthcare sector in the People's Republic of China (the "PRC").

The Company and its subsidiaries (collectively the "Group") aim to leverage on growth opportunities in the strong and growing domestic demand for high quality healthcare products in the PRC and build its portfolio companies into market sector leaders with competitive edge. Cathay has already demonstrated a strong track record of identifying high-growth potential investment opportunities in this area including: Lansen, a leading specialty pharmaceutical company focused on rheumatology and dermatology in the PRC; Haizi, a company engaged in the manufacture, marketing and sale of inositol and its by-product, di-calcium phosphate; Yangling, a company engaged in production and sales of plant extracts for use as key active ingredients in healthcare products; and Botai, a company engaged in collagen products.

The Group employs approximately 2,000 people across the PRC, including over 30 specialist corporate and business development staff based at the holding company's offices in Hong Kong and Shenzhen. Cathay also has a hotel investment.

For more information please visit the Company's website: www.cathay-intl.com.hk

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGFMMMTMBBTBAF

(END) Dow Jones Newswires

June 20, 2016 06:17 ET (10:17 GMT)